Legal Opinion
Merck Sharp & Dohme Corp. v. Hospira, Inc.
Court of Appeals for the Federal Circuit
Decided October 26, 2017No. 2017-1115PublishedCited by 13 opinions
1Opinion of the Court
Dissenting opinion filed by Circuit Judge Newman.
LOURIE, Circuit Judge.
Merck Sharp & Dohme Corp. (“Merck”) appeals from the decision of the United States District Court for the District of Delaware concluding, after a bench trial, that claims 21-34 (“the asserted claims”) of U.S. Patent 6,486,150 (“the ’150 patent”) are invalid under 35 U.S.C. § 103 (2006). See Merck Sharp & Dohme Corp. v. Hospira Inc., No. CV 14-915-RGA, 2016 WL 5872620, at *21 (D. Del. July 10, 2016) (Decision). Because the district court did not err in its conclusion of obviousness, we affirm.
Background
Merck owns the ’150…
2Cases cited8 opinions
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Merck & Co. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2005
- Wyers v. Master Lock Co.Court of Appeals for the Federal Circuit · 2010
- Apple Inc. v. Samsung Electronics Co., Ltd.Court of Appeals for the Federal Circuit · 2016
- Golden Blount, Inc. v. Robert H. Peterson Co.Court of Appeals for the Federal Circuit · 2004
3 more not listed; retrieve them via the Exa API.
3Cited by13 opinions
- Astrazeneca Ab v. Mylan Pharmaceuticals Inc.Court of Appeals for the Federal Circuit · 2021
- Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc.Court of Appeals for the Federal Circuit · 2018
- Adapt Pharma Operations v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2022
- Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2024
- Hospira, Inc. v. Fresenius Kabi USA, LLCDistrict Court, E.D. Illinois · 2018
8 more not listed; retrieve them via the Exa API.